Clinical trials in progress

The suitability of Tience for the treatment of acne scars is open-label, single-center, split-face, pseudo-randomized clinical trial. The purpose of the study is to investigate the efficacy and safety of Tience, a human-derived, cell-free adipose tissue product, in the treatment of moderate to severe acne scars. The study enrolls 20 healthy adults aged 18–40 with visible acne scarring on both cheeks.

Each participant receives three treatment sessions over a three-month period – on Day 0, Day 30, and Day 90 – administered via intradermal injections to acne-scarred areas on one side of the face. The other side remains untreated during the initial study phase and will be treated following the final evaluation period.

Clinical outcomes are assessed over a six-month follow-up period, using both the Visia® Gen7 skin analysis system and Goodman and Baron qualitative and quantitative grading scales to evaluate changes in scar severity and overall skin quality. The final study visit is scheduled for March 2026.

This study will evaluate the effect of an allogeneic adipose tissue extract (Tience) on wound healing at skin graft donor sites at Wellbeing Services County of Central Finland, Nova Hospital, Department of Plastic and Reconstructive Surgery.

Thirty adult patients scheduled for skin graft surgery will be enrolled. Each patient will have two skin graft donor sites harvested. One skin graft donor site wound will be treated topically with Tience, applied immediately after harvesting and reapplied on Day 3, while the other skin graft donor site wound will receive standard care.

The main outcome is the time to complete epithelialization of the skin graft donor site wound, as confirmed by investigators and independent evaluators. Secondary measures include wound characteristics, scar formation and scar quality, and monitoring of adverse events, such as wound deterioration. The estimated study completion date is February 2026.